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Abstract
Patient adherence to treatment is an important factor in the effectiveness of antiretroviral
regimens. Adherence to treatment could be monitored by estimation of antiretroviral drugs in
biological fluids. We aimed to obtain information on the quantity and duration of excretion of
lamivudine in urine following oral administration of a single dose of 300 mg and to assess its
suitability for adherence monitoring purposes. Spot urine samples were collected before dosing
and at 4, 8, 12, 24, 28, 32, 48, 72, and 96 hours post dosing from 10 healthy subjects, and lamivudine
was estimated by high-pressure liquid chromatography (HPLC). Lamivudine values were expressed
as a ratio of urine creatinine. About 91% of the ingested drug was excreted by 24 hours, and the
concentration thereafter in urine was very negligible. A lamivudine value of 0.035 mg/mg creatinine
or less at 48 hours is suggestive of a missed dose in the last 24 hours. The study findings showed
that estimation of urine lamivudine in spot specimens could be useful in monitoring patient
adherence to antiretroviral treatment. However, this needs to be confirmed on a larger sample size
and among patients on once-daily and twice-daily treatment regimens.
Introduction
Highly active antiretroviral therapy (HAART) allows
patients who are infected with HIV to live productive and
relatively disease-free lives for long periods. HAART is
composed of various classes of antiretroviral drugs. The
current standard care for the treatment of HIV-1 infection
is a triple-drug therapy with 2 nucleotide or nucleoside
reverse transcriptase inhibitors (NRTIs) forming the back-
bone in combination with a nonnucleoside reverse tran-
scriptase inhibitor (NNRTI) or protease inhibitor.[1,2]
Fixed-dose combinations (FDCs) of antiretroviral drugs
are widely used as first-line regimens in India, Africa, and
other developing/resource-constrained areas.[3,4] Two
combinations, zidovudine/nevirapine/lamivudine (ZDV/
NVP/3TC) and stavudine/nevirapine/lamivudine (d4T/
NVP/3TC), are available as FDCs in the developing world.
The advantages of using FDCs include convenience,
reduction in prescription errors, reduced pill counts, and
potential for improved adherence.
Variability in response to antiretroviral agents has been
attributed in part to virologic, immunologic, pharmacok-
inetic factors and adherence differences between
patients.[5] Adherence to antiretroviral treatment is a
strong predictor of virologic suppression, disease progres-
sion, and death.[6-9] Clinical trials have suggested that
early and late virologic failures appeared to be related
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rather than the emergence of drug-resistant
viruses.[10,11] Hence, monitoring patient adherence to
treatment is important to ensure optimal outcomes. Iden-
tifying accurate predictors of adherence that can routinely
be applied in clinical practice will be of value.
Currently available approaches to measure adherence
include (1) patients' self-report, (2) physician assess-
ments, (3) electronic monitoring, (4) pill count, and (5)
prescription-refill compliance. Although these methods
have proved to be predictive of outcomes, the results are
variable.[7] Some investigators have assessed antiretrovi-
ral drug levels in the blood as a measure of adher-
ence.[12,13] Alternatively, urine could serve as a useful
biological fluid for measuring antiretroviral drug levels,
particularly to monitor patient adherence to treatment, if
found feasible. Such a method would be noninvasive and
simple to perform. This method is applied in tuberculosis
therapy, in which the detection of acetyl isoniazid in urine
indicates intake of isoniazid within the past 24 hours.[14]
In a study carried out at our center, it was observed that a
single oral dose of NVP administered to healthy subjects
was excreted in urine for up to 9 days. This could be due
to the long half-life of NVP (3035 hours). It was therefore
apparent that urine NVP would not be a useful predictor
of antiretroviral adherence.[15] We hypothesized that a
similar approach could be tested with other antiretroviral
drugs, which have a shorter half-life and could be detected
easily in urine.
3TC (2'-deoxy-3'-thiacytidine), a cytosine nucleoside ana-
log, is being effectively used in combination with other
antiretroviral drugs to treat HIV-1 infection. It is potent
against HIV, well tolerated, and does not require any rig-
orous schedule with respect to food. 3TC could serve as a
useful candidate for monitoring patient adherence to
antiretroviral treatment because it has several advantages:
It is present in all FDC pills; it has a shorter elimination
half-life than NVP (about 57 hours); the primary route of
elimination is renal; and the major portion (70%) of an
oral dose is excreted unchanged as a parent compound.
3TC is a prodrug and undergoes phosphorylation by
intracellular kinases to form 3TC-5'-triphosphate, the
active metabolite that prevents viral replication. This com-
pound has a long intracellular half-life of 15.5 hours.
Because 3TC requires intracellular activation, it has been
hypothesized and proved that the intracellular level of the
active triphosphate metabolite rather than unchanged
drug levels in plasma correlate with virologic response in
HIV-infected patients.[16] It has also been shown that
3TC, when administered at the recommended dosage of
150 mg twice daily, produces serum concentrations con-
sistently above the in vitro IC50 against HIV-1 in various
cell lines.[17]
In order to assess the feasibility of using 3TC detection in
urine as a predictor of antiretroviral treatment adherence,
it is important to obtain information on the amount and
extent of excretion of a single dose of the drug. Very lim-
ited information is available on the pattern of urinary
excretion of 3TC, and no attempts have been made to use
this as a test of adherence. This, however, requires a sim-
ple method to estimate 3TC in urine. Morris and Selin-
ger[18] have described a high-pressure liquid
chromatographic (HPLC) method for determination of
3TC in urine, which allows direct injection of urine with
column switching. This method requires 2 columns, one
for getting rid of unwanted urine constituents and the
other for elution of 3TC and analysis. We have developed
a simple method for estimation of 3TC concentrations in
urine by direct injection of suitably diluted urine (1:10/
1:50) and analysis with a 150-mm column with UV detec-
tion. This method was applied to estimate urine 3TC con-
centrations in the urine of healthy volunteers who were
administered a single oral dose of 300 mg of 3TC. The aim
of the study was to obtain information on the quantity
and duration of excretion of 3TC in urine and assess its
suitability for adherence monitoring purposes.
Methods
Estimation of Urine 3TC by HPLC
Chemicals
3TC tablets (Retrolam 150) were obtained from Alkem
Laboratories Ltd., India. Pure 3TC powder was a kind gift
from Aurobindo Pharma, Hyderabad, India. Methanol
(HPLC-grade) and potassium dihydrogen orthophos-
phate were purchased from Qualigens, India. Deionized
water was processed through a Milli-Q water purification
system (Millipore, Billerica, Massachusetts).
Chromatographic System
The HPLC system (Shimadzu Corporation, Kyoto, Japan)
consisted of 2 pumps (LC-10ATvp), diode array detector
(SPD-M10Avp), and system controller (SCL-10Avp). A
rheodyne manual injector (Rheodyne, Cotati, California)
attached with a 20-microliter (mcL) sample loop was used
for loading the sample. ClassVP-LC workstation was used
for data collection and acquisition. The analytic column
was a C18, 150 × 4.6 mm inner diameter, 5-micron particle
size (Lichrospher 100 RP-18e, Merck, Germany) protected
by a compatible guard column.
The mobile phase consisted of 50 mM phosphate buffer
pH 4.0 and methanol (85:15 volume/volume) containing
0.05% triethylamine. Prior to preparation of the mobile
phase, the phosphate buffer and methanol were degassed
separately with a Millipore vacuum pump. The UV detec-Page 2 of 6
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minutes at a flow rate of 0.75 mL/minute at ambient tem-
perature. Unknown concentrations were derived from lin-
ear regression analysis of the peak height vs concentration
curve.
3TC Concentration Curve
The concentration curve was set up with a set of 3TC
standards ranging from 2.5 to 50.0 micrograms (mcg)/
mL. The standards were prepared from a stock solution
with suitably diluted normal 3TC-free urine. The linearity
of the standard concentrations was verified with estimates
of the correlation coefficient (r). The intraday and inter-
day variations of 3TC standards were determined by
processing each standard concentration in duplicate for 6
consecutive days.
Assay Specificity
Interference from endogenous compounds was investi-
gated by analyzing blank urine samples obtained from 6
male and 6 female subjects. Interference from certain
antiretroviral drugs, namely, NVP, efavirenz, ZDV, dida-
nosine, d4T, indinavir, and nelfinavir; antituberculosis
drugs, such as rifampicin, isoniazid, pyrazinamide,
ethambutol, streptomycin; and other commonly coad-
ministered medications, such as ofloxacin, acetozola-
mide, loperamide, prednisolone, diphenylhydantoin,
amitriptyline, cotrimoxazole, and fluconazole at a high
concentration of 50 mcg/mL, was also evaluated.
3TC Stability in Urine
The stability of 3TC in human urine when stored at -20°C
was evaluated by assaying 10 urine samples containing
3TC on days 1 and 7.
Study in Healthy Volunteers
Ten adult, healthy volunteers aged 18 years and older,
including 7 men and 3 women, took part in the study.
Their mean age and body weight were 39 years and 63 kg,
respectively. All of the volunteers underwent physical
examination by a medical officer. None of the volunteers
had been suffering from any illness or taking concurrent
medications at the time of the study. The purpose of the
study was explained to the study participants, and only
those who were willing to participate were included.
Informed written consent was obtained from all of the
study participants before they took part in the study.
Smokers, chronic alcoholics, and women on hormonal
birth control pills were not included in the study.
All of the volunteers were requested to report to the clinic
division of the Tuberculosis Research Centre, Chennai,
India, in the morning after an overnight fast. On the day
of the study, a sample of urine was collected (0 hour) in a
labeled container. Two tablets of 150 mg 3TC (300 mg)
were administered in about 200 mL of water. They were
instructed to collect spot urine samples at 4, 8, 12, 24, 28,
32, 48, 72, and 96 hours after drug administration. All of
the urine samples were stored at -20°C until assay. The
3TC concentration in the urine samples was estimated
according to the method described in this study. 3TC con-
centrations were expressed as a ratio of urine creatinine
concentration. Urine creatinine was estimated by a color-
imetric method that is based on Jaffe's reaction.[19]
Results
The calibration curve parameters of 3TC from 6 individual
experiments for standard concentrations ranging from 2.5
to 50.0 mcg/mL showed a linear relationship between
peak height and concentration. The correlation coefficient
(r) values ranged from 0.99577 to 0.99999. The linearity
and reproducibility of the various standards used for con-
structing calibration graphs for urine 3TC are given in
Table 1 . The intraday and interday relative standard devi-
ation (RSD) for standards 2.550.0 mcg/mL ranged from
0.3% to 4.0% and 3.2% to 7.2%, respectively. The accu-
racy of the method was 102%. The mean urine 3TC con-
centrations measured on days 1 and 7 in 10 urine samples
Table 1: Linearity and Reproducibility of Urine Lamivudine Standards
Mean Peak Height ± SD (RSD %)
Standard Concentration (mcg/mL) Intraday (n = 6) Interday (n = 6)
2.5 7948 ± 211 (2.7) 8019 ± 571 (7.1)
5.0 15,534 ± 308 (2.0) 15,424 ± 1110 (7.2)
12.5 40,042 ± 1388 (3.4) 37,916 ± 2743 (7.2)
25.0 75,985 ± 3063 (4.0) 72,825 ± 4733 (6.5)
50.0 152,533 ± 388 (0.3) 151,735 ± 4824 (3.2)
mcg = micrograms; RSD = relative standard deviation; SD = standard deviationPage 3 of 6
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dation of 3TC in urine occurred up to 1 week when stored
at -20°C.
Urine 3TC concentrations were calculated from the cali-
bration standard curve and multiplied by the appropriate
dilution factor. In order to account for variations in spot
urine volume, all 3TC values were expressed as a ratio of
creatinine concentration. Table 2 gives the 3TC values per
milligram of creatinine (mean and range) obtained in 10
healthy subjects.
Discussion
In most cases, HAART results in a reduction in plasma
viral load to below the limit of detection. Regardless of the
decrease in morbidity and mortality associated with
HAART regimens and the significant increase in the life
expectancy of treated HIV-infected individuals, eventual
failure of therapy is common and poses challenges for
future treatment. The failure of HAART most likely arises
from a combination of viral and host factors that facilitate
the emergence of HIV variants with resistance to multiple
antiretroviral drugs. The emergence of drug resistance in
patients receiving HAART can be primarily attributed to
the high spontaneous mutation rate and high rate of HIV
turnover in HIV-infected individuals, selective pressure
arising from antiretroviral therapy, pharmacokinetic char-
acteristics of antiretroviral drugs, patient tolerance/adher-
ence to antiretroviral regimens, and the existence of viral
reservoirs.[20]
Patient adherence is a highly important factor in the effec-
tiveness of antiretroviral regimens, and affects the evolu-
tion of viral variants with different degrees of sensitivity to
drugs.[21] Theoretically, total adherence should prevent
the emergence of resistant strains, but incomplete patient
adherence coupled with an array of other pharmacologic
factors results in the presence of a heterogeneous popula-
tion, and the possibility of selecting for viral resistance.
Many factors influence the degree of patient adherence to
therapy, such as side effects of drugs (toxicity), high costs
of antiretroviral regimens, and lack of infrastructure
needed to monitor their use. Currently available
approaches to measure adherence have notable limita-
tions,[22] and individual patient assessments by medical
providers do not accurately predict adherence.[23] Liechty
and coworkers[24] reported that an abnormally low,
untimed antiretroviral drug level can identify individuals
with very low adherence at high risk for HIV disease pro-
gression and death.
Monitoring compliance by measuring the presence of
indinavir in saliva has been reported.[25] A similar
approach with respect to urine levels of antiretroviral
drugs would be useful in monitoring adherence. Urine
collections are noninvasive and would be most suited to
the patients. In this study, we attempted to assess whether
a simple spot urine test for 3TC could help in monitoring
patient adherence to antiretroviral treatment. The reason
for choosing 3TC was that, apart from having a short elim-
ination half-life, it is present in the fixed-dose triple-/dou-
ble-drug combination of antiretroviral drugs commonly
used in resource-limited settings.
Information on analytic methods for estimation of urine
3TC is very limited. The method of Morris and Selin-
ger[18] allows direct injection of urine with HPLC column
switching followed by UV detection. They performed
Table 2: Lamivudine Concentrations in Spot Urine of 10 Healthy Subjects
Time After Drug Administration (hours) Mean (Range) (mg Lamivudine/mg Creatinine)
4 0.68 (0.270.99)
8 0.31 (0.150.46)
12 0.088 (0.0560.12)
24 0.036 (0.0120.059)
28 0.034 (0.0090.046)
32 0.024 (0.0060.035)
48 0.019 (0.0030.027)
72 0.015 (00.022)
96 0.009 (00.016)Page 4 of 6
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Corporation, Milford, Massachusetts) that was eluted
with deionized water. 3TC was retained in the column,
whereas the bulk of the urine constituents was eluted to
waste. The SCX column was then backflushed to a BDS-
Hypersil-C18 column (Keystone Scientific, Bellefonte,
Pennsylvania) and eluted with a mobile phase consisting
of acetate buffer and methanol. Direct injection of urine
to the analytic column would damage it and shorten its
life. One way to overcome this problem is by column
switching, as reported by Morris and Selinger.[18] How-
ever, this could be time-consuming and cumbersome.
Alternatively, urine could be adequately diluted and then
directly injected into the analytic column. This makes the
method very simple and rapid without causing any dam-
age to the column.
We made an attempt to standardize urine 3TC estimation
by suitably diluting the urine and directly injecting the
diluted urine into the HPLC column. Under the chroma-
tographic conditions described above, 3TC was resolved
as a single discrete peak at 3.5 minutes.
Because HIV-infected individuals receive treatment for
various opportunistic infections, it is important to estab-
lish the specificity of the method. No endogenous com-
pounds or antiretroviral drugs, such as NVP, efavirenz,
ZDV, didanosine, dT4, indinavir, and nelfinavir; antitu-
berculosis drugs, such as rifampicin, isoniazid, pyrazina-
mide, ethambutol, streptomycin; and other commonly
coadministered medications, such as ofloxacin, acetozola-
mide, loperamide, prednisolone, diphenylhydantoin,
amitriptyline, cotrimoxazole, and fluconazole, interfered
in the 3TC chromatogram (data not shown).
The method was applied for the determination of 3TC
concentration in spot urine collected at different time
points from 10 healthy subjects after they were adminis-
tered a single oral dose of 300 mg 3TC. The reason for
selecting the 300-mg once-daily dose was that many regi-
mens are now designed for once-daily use in order to
improve patient adherence. As expected, there was a
steady decline in 3TC concentrations excreted in urine
with time (see Table 2 ). A major portion of the drug is
excreted by 8 hours, and very negligible amounts of 3TC
up to 96 hours. In order to monitor patient adherence on
a once-daily regimen, an ideal test should be positive up
to 24 hours and negative beyond this period. In the case
of twice-daily regimens, the test should be negative after
12 hours. The mean 3TC values at 24 and 28 hours were
0.036 and 0.034 mg/mg creatinine, respectively. While
keeping a cutoff value of 0.035 mg (mean of above 2 val-
ues), it was observed that 2 patients each at 24 and 28
hours and 1 patient at 32 hours had 3TC concentrations
exceeding the cutoff value, and none at 48 hours and
beyond. Therefore, a 3TC concentration of 0.035 mg/mg
creatinine or less at 48 hours is suggestive of a missed dose
the previous day.
The study, which was conducted on a small number of
healthy subjects, has provided information on the extent
of excretion of a single dose of 300 mg 3TC. About 91%
of the ingested drug is excreted by 24 hours. The concen-
tration thereafter is very low. Patients undergoing antiret-
roviral treatment would be at steady state and excreting
slightly higher concentrations of the drug. The findings of
this study showed that estimation of 3TC in spot urine
could be useful in monitoring patient adherence to
antiretroviral treatment. However, these findings need to
be confirmed on a larger sample size among patients on
once-daily and twice-daily treatment. A simple urine test
would go a long way in monitoring antiretroviral adher-
ence in resource-constrained settings.
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